Aurealis Therapeutics: Funding, Investors & Team (Sep 2026)
Aurealis Therapeutics is a Swiss-Finnish Cell and Gene Therapy Platform Company. Our multi-target cell and gene therapy platform, based on genetically modified safe lactic acid bacteria, addresses unmet medical needs: Chronic Wounds - Diabetic Foot Ulcers, Venous Ulcers, Pressure Ulcers - deadly Cancers - Ovarian Cancer, Peritoneal Carcinomatosis - Inflammation. After successfully completing our Phase 1 clinical study in Diabetic Foot Ulcer (DFU) patients with our lead clinical product AUP-16, our DFU Phase 2 study is ongoing in Italy, Germany and Poland. Venous Ulcers and other ulcers will follow. In Oncology, we are building on impressive pre-clinical data with Oncolytic Bacteria lead candidate AUP-55, which shows increased survival in Ovarian Cancer and peritoneal carcinomatosis. Our pipeline also includes Inflammation, at discovery stage.
Aurealis Therapeutics has raised $9.1M across 1 funding round on record, the most recent an undisclosed round of $9.1M announced in Nov 2024.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Aurealis Therapeutics Company Profile and Key Stats
Latest funding round on record: Nov 2024.
Aurealis Therapeutics Funding Rounds
Aurealis Therapeutics Founders and Leadership Team
Contact details for the Aurealis Therapeutics team: 1 of 1 has an email address on file.
Start 14-day free trial →Aurealis Therapeutics Funding Compared to Other Biotechnology Startups
Aurealis Therapeutics' latest round of $9.1M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Aurealis Therapeutics in Biotechnology and Kuopio
Companies Similar to Aurealis Therapeutics
Solar Foods is a food-tech startup that focuses on utilizing a technology that involves using electricity to…
Algorithmiq utilizes its expertise in quantum information, complex systems, and computational physics to…
Bioretec Ltd. is a Finnish material technology company focused on the development, manufacturing and…
NPHarvest is a company with expertise in organic waste management, wastewater treatment, and nutrient…
They are a pioneering company driven by a passion for innovation and a commitment to solving their partners’…
StemSight is a startup focusing on cell therapy in Tampere, Finland, where they are working on innovative…
Herantis Pharma is a company focused on addressing medical needs that have not been met by current treatments.
Eevia Health is a Nordic life science company based in Finland and Norway, with headquarters in Seinäjoki and…
Nexstim is a medical device company focused on image-guided transcranial magnetic stimulation, dedicated to…
Enifer is a company that specializes in using fungal fermentation to create products from byproducts of the…
Onego Bio is a company based in the US and Finland that is transforming the food industry by utilizing…
Aurealis Therapeutics Funding FAQs
What does Aurealis Therapeutics do?
Aurealis Therapeutics is a Swiss-Finnish Cell and Gene Therapy Platform Company. Our multi-target cell and gene therapy platform, based on genetically modified safe lactic acid bacteria, addresses unmet medical needs: Chronic Wounds - Diabetic Foot Ulcers, Venous Ulcers, Pressure Ulcers - deadly Cancers - Ovarian Cancer, Peritoneal Carcinomatosis - Inflammation. After successfully completing our Phase 1 clinical study in Diabetic Foot Ulcer (DFU) patients with our lead clinical product AUP-16, our DFU Phase 2 study is ongoing in Italy, Germany and Poland. Venous Ulcers and other ulcers will follow. In Oncology, we are building on impressive pre-clinical data with Oncolytic Bacteria lead candidate AUP-55, which shows increased survival in Ovarian Cancer and peritoneal carcinomatosis. Our pipeline also includes Inflammation, at discovery stage.
How much funding has Aurealis Therapeutics raised?
Aurealis Therapeutics has raised $9.1M across 1 round on record. The most recent is an undisclosed round of $9.1M announced in Nov 2024.
When did Aurealis Therapeutics last raise funding?
Aurealis Therapeutics' most recent funding round on record is an undisclosed round of $9.1M, announced in Nov 2024.
Who founded Aurealis Therapeutics?
FundedIQ lists Juha Yrjanheikki (Founder) at Aurealis Therapeutics.
Where is Aurealis Therapeutics headquartered?
Aurealis Therapeutics is based in Kuopio, Eastern Finland, Finland.
How many employees does Aurealis Therapeutics have?
Aurealis Therapeutics is in the 11-50 employee band.
How does Aurealis Therapeutics' funding compare to other Biotechnology startups?
Aurealis Therapeutics' latest round of $9.1M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Aurealis Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Aurealis Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.